Cervical Cancer Prognosis

Overview

Cervical Cancer prognosis is the estimation of likely clinical outcomes, including survival, recurrence, and treatment response, for a person diagnosed with cancer of the cervix. Prognosis guides treatment planning and patient counseling and is derived from a combination of tumor, host, and system-level factors. The single most influential determinant is stage at diagnosis, reflecting depth of invasion, parametrial and nodal involvement, and distant spread; earlier-stage disease detected through screening generally carries a substantially better outlook than advanced disease. Additional prognostic features include histologic type and grade, tumor size, lymphovascular invasion, lymph node status, and resection margins, together with patient age, comorbidity, and overall health. Molecular characteristics are increasingly recognized, including activation of signaling pathways such as PI3K/AKT/mTOR that may influence aggressiveness and therapeutic response. Because the disease is largely caused by persistent high-risk human papillomavirus infection, the effectiveness of vaccination and screening in shifting diagnoses to earlier, more treatable stages strongly affects population-level outcomes, and low screening uptake is associated with later presentation and poorer prognosis. Prognostic assessment relies on staging investigations, pathology, imaging, and, increasingly, biomarker and molecular profiling. It informs decisions among surgery, radiotherapy, chemotherapy, and combined approaches, as well as surveillance for recurrence. Research examines the clinical, pathological, and molecular predictors of Cervical Cancer outcomes and the role of early detection in improving survival.

Research published in this journal

6 peer-reviewed articles, ranked by relevance. Each links to its DOI.

This page summarises published research for orientation; it is not medical or professional advice.

Related topics